Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Novartis' Zolgensma study halted by FDA amid safety questions
ZURICH (Reuters) - U.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2019
PRAC recommends measures to minimise risk of serious side effects with Lemtrada for multiple sclerosisEMA’s safety committee (PRAC) recommended restricting Lemtrada for use in adults with re...
Dicerna enters alliance to develop hepatitis B drugs
Dicerna Pharmaceuticals has signed a research collaboration and licensing agreement with Roche to create treatments for chronic hepatitis B virus (HBV) infection.
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
THOUSAND OAKS, Calif.
Bio-Techne investing up to $50M in new plant for recombinant proteins
With drugmakers like Pfizer expanding their cell and gene therapy operations, recombinant protein producer Bio-Techne says it needs a new plant to keep up with demand.
FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis
CAMBRIDGE, Mass.
Common early sign of cardiovascular disease also may indicate cancer risk, study finds
A Mayo Clinic-led study involving 488 cardiac patients whose cases were followed for up to 12 years finds that microvascular endothelial dysfunction, a common early sign of cardiovascular disease, is ...
Liver damage from drinking may one day be REVERSIBLE: Scientists are developing a drug to undo tissue scarring in lung and liver disease
Doctors may some day be able to reverse the damage that years of heavy drinking does to the liver, a new study suggests.
With 2 Failed Trials, Cyclerion Announces Plans to Cut 30 Out of 135 Jobs
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
Gilead, Glympse Bio to explore biomarker use in NASH
Gilead has announced a new strategic collaboration with Glympse, in order to explore the use of biomarker technology in nonalcoholic steatohepatitis (NASH) clinical development.
MorphoSys, Novartis, Galapagos abandon experimental MOR106
MorphoSys, Novartis and Galapagos have announced the premature end of the clinical development program of MOR106 in atopic dermatitis, citing “low probability to meet main goal of study.
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europ...
347
348
349
350
351
352
353
354
355
